WASHINGTON — Sparks flew between a patient advocate and a drug industry representative. The middlemen and the manufacturers reached a strained detente. Statistics were offered and disputed, as were policy options both controversial and staid.
Watch the video of our panel, where STAT Washington editor Erin Mershon and Washington correspondent Ike Swetlitz facilitated a wide-ranging discussion between representatives of some of the powerful players in the drug pricing world of Washington. Panelists at the Thursday event included Kristin Bass, senior vice president of policy and federal affairs at the PBM trade group PCMA; Jenny Bryant senior vice president of policy and research at the manufacturer trade group PhRMA; Jane Horvath, a consultant for Horvath Health Policy; and David Mitchell, president of the patient advocacy group Patients for Affordable Drugs.